Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 5/2014

01-05-2014 | Original Paper

“Set it and Forget it”: Women’s Perceptions and Opinions of Long-Acting Topical Vaginal Gels

Authors: Jacob J. van den Berg, Rochelle K. Rosen, Dana E. Bregman, Lara A. Thompson, Kathleen M. Jensen, Patrick F. Kiser, David F. Katz, Karen Buckheit, Robert W. Buckheit Jr., Kathleen M. Morrow

Published in: AIDS and Behavior | Issue 5/2014

Login to get access

Abstract

Women’s initial understandings and anticipated acceptability of long-acting vaginal gels as potential anti-HIV microbicides was investigated by exploring the perceptibility variables associated with prototype formulations. Four focus groups with 29 women, aged 18–45, were conducted to consider gel prototypes with varied physicochemical and rheological properties. Participants responded favorably to the concept of long-acting vaginal gels as microbicides. Distinctions in understandings and stated needs regarding product dosing, characteristics, and effectiveness offer valuable insights into product design. Long-acting vaginal gels capable of protecting against HIV/STIs will be a viable option among potential users, with dosing frequency being an important factor in willingness to use.
Literature
1.
2.
3.
4.
Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423–34.PubMedCrossRef
5.
6.
Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168–74.PubMedCentralPubMedCrossRef
7.
8.
Romano J, Malcolm RK, Garg S, Rohan LC, Kaptur PE. Microbicide delivery: formulation technologies and strategies. Curr Opin HIV AIDS. 2008;3:558–66.PubMedCrossRef
9.
10.
Johnson TJ, Clark MR, Albright TH, et al. A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis. Antimicrob Agents Chemother. 2012;56:6272–83.PubMedCentralPubMedCrossRef
11.
Tasoglu S, Rohan LC, Katz DF, Szeri AJ. Transient swelling, spreading, and drug delivery by a dissolved anti-HIV microbicide-bearing film. Phys Fluids. 2013;25:31901.CrossRef
12.
Carballo-Diéguez A, Dolezal C, Bauermeister JA, O’Brien W, Ventuneac A, Mayer K. Preference for gel over suppository as delivery vehicle for a rectal microbicide: results of a randomised, crossover acceptability trial among men who have sex with men. Sex Transm Infect. 2008;84(6):483–7.PubMedCentralPubMedCrossRef
13.
Mohammed Fayaz A, Ao Z, Girilal M, et al. Inactivation of microbial infectiousness by silver nanoparticles-coated condom: a new approach to inhibit HIV- and HSV-transmitted infection. Int J Nanomed. 2012;7:5007–18.
14.
15.
Singer R, Mawson P, Derby N, et al. An intravaginal ring that releases the NNRTI MIV-150 reduces SHIV transmission in macaques. Sci Transl Med. 2012;4:150ra123.PubMedCrossRef
16.
Baum MM, Butkyavichene I, Gilman J, et al. An intravaginal ring for the simultaneous delivery of multiple drugs. J Pharm Sci. 2012;101:2833–43.PubMedCrossRef
17.
Kiser PF, Johnson TJ, Clark JT. State of the art in intravaginal ring technology for topical prophylaxis of HIV infection. AIDS Rev. 2012;14:62–77.PubMed
18.
Clark MR, Johnson TJ, McCabe RT, et al. A hot-melt extruded intravaginal ring for the sustained delivery of the antiretroviral microbicide UC781. J Pharm Sci. 2012;101:576–87.PubMedCrossRef
19.
20.
Severy LJ, Newcomer S. Critical issues in contraceptive and STI acceptability research. J Soc Issues. 2005;61:45–65.CrossRef
21.
Severy LJ, Tolley E, Woodsong C, Guest G. A framework for examining the sustained acceptability of microbicides. AIDS Behav. 2005;9(1):121–31.PubMedCrossRef
22.
Mantell JE, Myer L, Carballo-Diéguez A, et al. Microbicide acceptability research: current approaches and future directions. Soc Sci Med. 2005;60(2):319–30.PubMedCrossRef
23.
Darroch JE, Frost JJ. Women’s interest in vaginal microbicides. Fam Plan Perspect. 1999;31(1):16–23.CrossRef
24.
Hammett TM, Mason TH, Joanis CL, et al. Acceptability of formulations and application methods for vaginal microbicides among drug-involved women: results of product trials in three cities. Sex Transm Dis. 2000;27(2):119–26.PubMedCrossRef
25.
Whitehead SJ, Kilmarx PH, Blanchard K, et al. Acceptability of Carraguard vaginal gel use among Thai couples. AIDS. 2006;20(17):2141–8.PubMedCrossRef
26.
Kamali A, Byomire H, Muwonge C, et al. A randomised placebo-controlled safety and acceptability trial of PRO 2000 vaginal microbicide gel in sexually active women in Uganda. Sex Transm Infect. 2010;86(3):222–6.PubMedCrossRef
27.
Morrow KM, Fava JL, Rosen RK, et al. Designing preclinical perceptibility measures to evaluate topical vaginal gel formulations: relating user perceptions and experiences to formulation properties. AIDS Res Hum Retroviruses. 2013. doi:10.​1089/​AID.​2013.​0099.
28.
Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77–101.CrossRef
29.
Turner AN, Van Damme K, Jamieson DJ, et al. Predictors of adherent use of diaphragms and microbicide gel in a four-arm, randomized pilot study among female sex workers in Madagascar. Sex Transm Dis. 2009;36(4):249–57.PubMedCrossRef
30.
van der Straten A, Van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of pre-exposure prophylaxis trials for HIV prevention. AIDS. 2012;26(7):F13–9.PubMedCrossRef
Metadata
Title
“Set it and Forget it”: Women’s Perceptions and Opinions of Long-Acting Topical Vaginal Gels
Authors
Jacob J. van den Berg
Rochelle K. Rosen
Dana E. Bregman
Lara A. Thompson
Kathleen M. Jensen
Patrick F. Kiser
David F. Katz
Karen Buckheit
Robert W. Buckheit Jr.
Kathleen M. Morrow
Publication date
01-05-2014
Publisher
Springer US
Published in
AIDS and Behavior / Issue 5/2014
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-013-0652-4

Other articles of this Issue 5/2014

AIDS and Behavior 5/2014 Go to the issue

Original Paper

Adherence in the CAPRISA 004 Tenofovir Gel Microbicide Trial

Original Paper

Attitude and Behavior Changes Among Gay and Bisexual Men After Use of Rapid Home HIV Tests to Screen Sexual Partners

Original Paper

Promoting Regular Testing: An Examination of HIV and STI Testing Routines and Associated Socio-Demographic, Behavioral and Social-Cognitive Factors Among Men Who have Sex with Men in New South Wales, Australia

Brief Report

Male Circumcision Coverage, Knowledge, and Attitudes After 4-Years of Program Scale-up in Rakai, Uganda

Original Paper

Assessing Adherence in the CAPRISA 004 Tenofovir Gel HIV Prevention Trial: Results of a Nested Case–Control Study

Original Paper

Correlates of HIV Testing Refusal Among Emergency Department Patients in the Opt-Out Testing Era
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits